Schultze Special Purpose Drops a “Teaser” Ahead of Extension Vote
by Kristi Marvin on 2020-06-01 at 11:16am

We have another teaser….this morning, Schultze Special Purpose Acquisition Corp. (SAMA), announced ahead of their forthcoming deadline extension vote that they have signed a non-binding LOI with Clever Leaves, a multi-national cannabis operator.

Interestingly, this is not a teaser where the SPAC makes you guess who they’re buying.  Instead, SAMA is stating exactly who it is they’re negotiating with and have even provide quotes from Clever Leave’s CEO.  This deal sounds fully-baked and yet they still do not have signed a definitive agreement. Perhaps Clever Leaves is waiting to see the results of the extension vote and how much cash is left in trust before they commit to terms. However, without a signed definitive agreement, we can’t technically move SAMA into the “announced” column just yet.

Nevertheless, today’s press release did provide some information on the intended target.  Clever Leaves operates globally with operations and facilities in Colombia, Portugal, the United States, Canada and Germany, producing pharmaceutical grade cannabis. The Company currently cultivates in over 1.9 million square feet of greenhouses, making it one of the largest cannabis cultivation and extraction companies globally.  Clever Leaves is also in the process of becoming one of the few cannabis companies in the world, and the only cannabis company in Latin America, to be granted a European Union Good Manufacturing Practice (“EU GMP”) certification for extracts, subject to successful completion of the certification process.

We currently have seven cannabis-focused SPACs out searching for targets, but it appears SAMA, which initially intended to focus on restructured companies, beat them all to announcing a cannabis combination.  To-date, only MTech (now Akerna – KERN) has closed a cannabis combination.  Although, Akerna was only “cannabis-adjacent” since it provided compliance technology to the sector, i.e., it was not involved in production or distribution.  If SAMA does “definitively” announce and this looks like a good deal, this could be the shot in the arm the rest of the field needs to announce their own cannabis deals. A “contact high”, so to speak.

SAMA goes to a vote next Tuesday, June 9th, and it sounds like we can expect a full announcement and definitive agreement shortly thereafter.  We’ll have to wait and see.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved